NEW DELHI, Oct 8 (Reuters) – Merck & Co’s (MRK.N) experimental antiviral drug molnupiravir has not shown “significant efficacy” against moderate COVID-19, a source with the Drug Controller General of India said.
Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator’s expert committee said on Friday.
link
Merck drug no “significant efficacy” against moderate COVID: India regulatory source
